<% (signals.list.current.rate).substr(0,7) %>
<% signal.analyst %>
<% signal.analyst %>
Last Updated: Dec 24, 2025 09:31:12 AM (GMT)
JAZZ: The current market price stands at 169.50, reflecting a notable increase of 2.15% since the previous close.
Support and Resistance Levels Three support levels are established at 167.00, 166.50, and 166.00, while resistance is identified at 170.00. The pivot point is calculated at 168.50.
Indicators The RSI recently peaked at 92.17, signaling overbought conditions. ATR measures high volatility at 0.32715, while the ADX indicates a strong trend at 100. The 50-day SMA is 169.51, and the 200-day EMA is 167.58. Parabolic SAR shows a bullish signal.
Market Sentiment With the price above the pivot point of 168.50 and favorable indicators, a bullish trend is predicted.
JAZZ Signals & Technical Analysis
Market Sentiment
Trend Indicators
Oscillators
Moving Averages
Pivot
About (JAZZ) Jazz Pharmaceuticals plc
Company Background
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, with significant operations in the United States. Established in 2003, the company specializes in the development and commercialization of innovative medicines for patients with unmet medical needs, particularly in the areas of neurology, psychiatry, and oncology. Jazz’s dedication to science-led innovation has positioned it as a leader in the industry, focusing on both rare diseases and common conditions that significantly impact patients' quality of life.
Market Position
Listed on NASDAQ under the ticker symbol JAZZ, Jazz Pharmaceuticals has established a strong market presence, driven by a robust portfolio of therapies. The company is recognized for its pioneering work in sleep medicine with its flagship product, Xyrem (sodium oxybate), and its expansion into the oncology sector with innovative treatments that address complex cancers. As a key player in the biopharmaceutical field, Jazz frequently explores strategic partnerships and acquisitions to enhance its product offerings and broaden its market reach.
Key Financial Highlights
Jazz Pharmaceuticals has demonstrated significant financial growth and stability, consistently outperforming market expectations. For the fiscal year 2022, the company reported a revenue increase of 10% year-over-year, largely attributed to the strong performance of its leading products and the successful launch of new therapies. With a diversified revenue stream and a commitment to research and development, Jazz remains focused on advancing its pipeline, which includes several promising candidates in clinical trials. The company's strong balance sheet, coupled with a strategic approach to operational efficiency, positions Jazz well for future growth in the competitive biopharmaceutical landscape.
Industry Highlights
In the rapidly evolving biopharmaceutical industry, Jazz Pharmaceuticals is committed to leveraging cutting-edge research and technology to deliver innovative healthcare solutions. The company's focus on rare diseases and niche markets allows it to address significant unmet medical needs while maintaining a competitive edge. As healthcare continues to transform, Jazz’s proactive approach to drug development and market expansion reinforces its position as a key player in improving patient outcomes worldwide.
Related Stocks
Sidebar rates
- <% signal.pair %>
<% signals.active.Current.rate.substr(0,7) %>
